Latest news with #ActivePharmaceuticalIngredient
News18
3 days ago
- Business
- News18
UP's Much-Awaited Pharma Park All Set To Become A Reality By 2027
Last Updated: With construction underway on over 350 acres in the first phase, the project is expected to catalyse investments worth over Rs 12,000 crore Uttar Pradesh's much-awaited Pharma Park is all set to become a reality by 2027 as the state government begins work on North India's first bulk drug and formulation hub in Lalitpur. With construction underway on over 350 acres in the first phase, the project is expected to catalyse investments worth over Rs 12,000 crore and boost UP's bid to become a national pharmaceutical manufacturing powerhouse. Spearheaded by the Uttar Pradesh State Industrial Development Authority (UPSIDA), the Lalitpur Bulk Drug Pharma Park is part of UP government's move to make the state self-reliant in bulk drug and Active Pharmaceutical Ingredient (API) production, while transforming Bundelkhand into an industrial powerhouse. Spread over 1,472 acres, the park is being developed in phases. Construction work for the first phase, covering 353 acres, is already underway. According to UPSIDA, environmental clearances have been secured, and land allotment to industries has begun. UPSIDA regional manager Sandeep Kumar confirmed that four pharmaceutical companies have submitted applications to set up units within the park. Of these, IJ Pharma and Badariya Pharma have already been allotted plots, while Riddhi Siddhi Pharma and JBJM Pharmaceuticals are in the final stages of the allotment process. 'Contracts with two companies are complete, while documentation for the remaining two is ongoing," Kumar said. The project has already caught the attention of prominent investors. During a recent investment roadshow in Ahmedabad, several pharma companies signed key proposals. UPSIDA CEO Mayur Maheshwari stated that the authority will conduct similar outreach initiatives in Mumbai, Chandigarh, and Hyderabad to attract more pharma players. Maheshwari described the park as a 'state-of-the-art plug-and-play facility" tailored to meet global standards. 'All utilities—electricity, water, waste management—are being designed for 24/7 industrial support. The entire park will be based on Zero Liquid Discharge (ZLD), ensuring that no untreated wastewater leaves the premises," he said. The park's underground utility network will include steam and solvent recovery systems, climate-controlled warehouses, and dedicated logistics corridors. A waste management system with a 3.53 TPD capacity, 33/11 KV sub-stations, and a 75 TPH steam distribution system will be in place to ensure operational efficiency. Safety and support infrastructure are also in focus. Plans include CCTV surveillance, boundary fencing, emergency service centers, and in-house skilling centres for local manpower training. Affordable housing for workers and executives is also under development within the premises. Investor Incentives UPSIDA has rolled out a special industrial land allotment scheme for the pharma park. Plots are priced at Rs 1,914 per square meter, with an additional 2 per cent discount for one-time payment. These rates, according to UPSIDA officials, are highly competitive compared to other pharma hubs in India and are expected to attract significant interest from small and mid-sized pharmaceutical players. 'Infrastructure, regulatory clearances, and affordability are all aligned to offer investors a compelling alternative to Gujarat or Hyderabad," said Maheshwari. The Lalitpur Pharma Park has already begun attracting significant industrial investments. CSL Life Sciences Pvt Ltd has proposed a Rs 200 crore investment to set up two manufacturing units—an IV Bottle Plant and an Oral Solid Dosage (OSD) Plant—spread over 5 to 7 acres. These units are expected to generate employment for over 250 people and become operational within the next two years. In addition, Mediheath Diagnostic Pvt Ltd is establishing a healthcare and diagnostic unit on a 4,200-square-meter plot, while Gaman Irradiation has announced plans to invest Rs 35 crore in a skin treatment and irradiation facility that is projected to create around 150 jobs within 24 to 36 months. Another major entrant, Obmed Pharma, has committed Rs 200 crore for setting up a formulation unit on a five-acre plot, which is expected to employ approximately 100 workers. These early investments signal strong industry confidence in the project and are expected to accelerate momentum as the park gains visibility on the national pharmaceutical landscape. Strong Connectivity The Lalitpur pharma park benefits from excellent multi-modal connectivity. The site is linked via MDR 35B, with NH-44 and NH-539 nearby, and is connected by rail through Tikamgarh and Lalitpur Junction. Air connectivity is facilitated via Khajuraho Airport (125 km away) and Lucknow Airport (385 km away). The proximity to the Jhansi node of the Uttar Pradesh Defence Corridor adds strategic value, as does its alignment with the state's broader goal of becoming a $1 trillion economy. According to Maheshwari, the Lalitpur pharma park is being developed in collaboration with leading national institutions like IIT, DRDO, and private consultancy firm Assystem India Limited, which has experience working on world-class pharma parks in Visakhapatnam. top videos View all 'We're not just matching global standards — we're aiming to surpass them," he said. 'Uttar Pradesh is well-positioned to fill the gap left after tax benefits in Himachal Pradesh ended. With the right policies, infrastructure, and investor confidence, we're ready to take the lead in pharma manufacturing." With construction in full swing, the park is expected to show physical results within two years, potentially transforming Lalitpur into India's premier bulk drug manufacturing hub. First Published: News india UP's Much-Awaited Pharma Park All Set To Become A Reality By 2027
Business Standard
18-06-2025
- Business
- Business Standard
Alembic Pharma receives USFDA EIR for Karakhadi API facility
Alembic Pharmaceuticals said that it has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its Active Pharmaceutical Ingredient (API)-III facility in Karakhadi, Gujarat. The inspection was conducted at the API-III facility from 17th March 2025 to 21st March 2025. Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. It manufactures and markets generic pharmaceutical products all over the world. Its research and manufacturing facilities are approved by regulatory authorities of many developed countries, including the USFDA. The companys consolidated net profit declined 12% to Rs 156.89 crore despite a 16.7% jump in net sales to Rs 1,769.64 crore in Q4 FY25 over Q4 FY24. Shares of Alembic Pharmaceuticals shed 0.78% to Rs 962.70 on the BSE.
Business Upturn
12-06-2025
- Business
- Business Upturn
Top stocks to watch today, June 12: ONGC, Oil India, Zydus, Waaree Energies, RailTel, Paytm and more
Indian equity markets extended gains on Wednesday, June 11, tracking positive global cues and supported by continued foreign fund inflows. The benchmark BSE Sensex rose by 123.42 points or 0.15% to close at 82,515.14. The broader NSE Nifty advanced by 37.15 points or 0.15%, ending at 25,141.40. This marked the sixth consecutive session of gains for the Nifty. On Thursday, June 12, several stocks are expected to remain in focus following company-specific developments and announcements. Stocks to Watch on June 12: 1. ONGC, Oil India (OIL): Crude oil prices surged over 4% amid rising tensions in West Asia. Brent crude approached the $70 per barrel mark, potentially impacting oil exploration and marketing companies (OMCs) and downstream sectors like paints and aviation. 2. Zydus Lifesciences: The US FDA has cleared the company's Active Pharmaceutical Ingredient (API) manufacturing facility in Dabhasa, Gujarat. An Establishment Inspection Report (EIR) has been issued, which indicates successful completion of the inspection. 3. Sterlite Technologies (STL)/Dilip Buildcon: The joint venture of STL and Dilip Buildcon secured a contract from BSNL under the BharatNet project. The order, valued at ₹2,631 crore, covers network deployment in Jammu & Kashmir and Ladakh. 4. Waaree Energies: The company signed a Power Purchase Agreement (PPA) for 150 MW out of its 170 MW solar project capacity. The agreement is with Rewa Ultra Mega Solar Ltd and MP Power Management Company Ltd. 5. RailTel Corporation: RailTel received a work order worth ₹12 crore from South Eastern Coalfields Ltd. The scope includes IT and communication-related infrastructure services. 6. City Union Bank: The bank's board approved raising up to ₹500 crore through Qualified Institutional Placement (QIP), subject to regulatory and shareholder approvals. 7. SEPC Ltd: SEPC has been awarded a Letter of Award (LoA) from Parmeshi Urja Ltd for executing a 133 MW AC solar project across 26 locations in Maharashtra. The total project value is ₹650 crore. 8. HG Infra Engineering: HG Infra was declared the lowest bidder for an interstate transmission system project under the Eastern Region Generation Scheme-I in Odisha. The contract spans 35 years with expected annual transmission charges of ₹43 crore. 9. Northern Arc Capital: The Reserve Bank of India (RBI) has granted approval to Northern Arc to commence and operate as a factoring business under relevant regulatory provisions. 10. Lemon Tree Hotels: The company announced the signing of a new property in Madhya Pradesh. The hotel will feature 72 rooms and expand the company's footprint in the central Indian market. 11. OMCs and Paint Companies: With crude oil prices climbing over geopolitical tensions, stock movements in oil marketing companies and industries dependent on crude derivatives, such as paints, may witness volatility. 12. Paytm: The Ministry of Finance clarified that speculation around Merchant Discount Rate (MDR) being applied to UPI transactions is unfounded and baseless, impacting sentiment around digital payment stocks. 13. MCX: The National Stock Exchange (NSE) received SEBI's approval to launch electricity futures, introducing competition in the energy derivatives market. 14. C.E. Info Systems (MapmyIndia): PhonePe is reportedly planning to offload up to a 5% stake in the company via block deals. The floor price is expected to be at a 10% discount to the current market price. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Business Standard
10-06-2025
- Business
- Business Standard
Zydus Life receives USFDA EIR for Dabhasa API facility
Zydus Lifesciences announced that it has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its Active Pharmaceutical Ingredient (API) manufacturing facility located at Dabhasa, near Vadodara. The facility underwent an inspection from April 21 to April 25, 2025. The inspection has been classified as Voluntary Action Indicated (VAI), with the FDA confirming the inspection as "closed". The companys consolidated net profit shed 0.96% to Rs 1,170.9 crore on 17.21% rise in revenue from operations to Rs 6290.2 crore in Q4 FY25 over Q4 FY24. Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. Shares of Zydus Lifesciences rose 0.71% to Rs 980 on the BSE.
Business Standard
06-06-2025
- Business
- Business Standard
Carbogen Amic AG to co-invest in its manufacturing sites in Switzerland
Dishman Carbogen Amcis' wholly owned subsidiary, CARBOGEN AMCIS AG, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced a strategic co-investment of more than CHF 25 million with a long-standing Japanese customer to expand manufacturing capabilities at its sites in Aarau and Neuland, Switzerland. The investment will support the production of a drug linker for a commercial antibody-drug conjugate (ADC), enabling CARBOGEN AMCIS to meet rising global demand. As part of the agreement, both facilities will see significant equipment and infrastructure enhancements, including: Aarau site: installation of 850-litre reactors and 0.4 m agitated filter dryers with supporting equipment. Completion is expected by Q1 2027. Neuland site: installation of 850-litre reactors and 0.4 m agitated filter dryers with auxiliary systems. Completion is anticipated by Q3 2027. This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021 to develop a site extension at the Bubendorf site in Switzerland, reinforcing the strength of the relationship and their shared commitment to long-term growth.
